Learn

Return Health Believes Psychedelics Can Treat Dementia
There is currently no known cure for dementia, but Return Health CEO Dr. James Kuo says psychedelics offer "unprecedented" potential....
Recent study interviews 23 underground psychedelic therapy practitioners about the biggest ethical issues and boundary challenges they face while sharing...
This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs...
Ethnobotanist Joseph Mays discusses "the key to all life," and Indigenous reciprocity on the latest Psychedelic Spotlight Podcast episode....
Researchers say there are several ways classic psychedelics could, directly and indirectly, lead to improved cardiometabolic health....
Our resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time....
Food and Drug Administration grants psychedelic biotechnology company PharmaTher orphan drug designation for ketamine to treat complex regional pain syndrome....
Silo Wellness CEO Douglas K. Gordon tells Psychedelic Spotlight that this is a "crucial" step toward "the mainstream acceptance of...
We owe so much of our understanding of these compounds to Indigenous peoples, and the widespread bioprospecting projects taking place...
CEO James Lanthier compares psychedelic medicines to aspirin, and explains why the company's lead candidate may be better than psilocybin....